Who we are

Sarah is living with a urea cycle disorder
Sarah is living with a urea cycle disorder

We care about rare disease patients

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.

  • Our research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases.
  • We market and make available across Europe, the Middle East, North Africa and Russia a portfolio of specialty and rare disease products for partner companies.
  • We have world-class capabilities in protein biochemistry and biologics manufacturing development - validated by leading industry partners. 
  • We manufacture the drug substance for the haemophilia treatment ReFacto AF/Xyntha® for the global market.

Global reach
Our organisation spans 24 countries, delivering therapies to patients in 67 countries across the globe. 

Opouštíte webové stránky SOBI

Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.

Přejete si opustit stránky?

Ano    Ne